What is BIIB's current stock price?

As of now, BIIB is trading at $179.89, with a daily change of +2.14%.

What are the risks associated with BIIB stock?

BIIB has Low, risk level based on volatility, sector strength, volume, investor confidence and outlook.

Market Overview Trending Stocks Stock Screener Trade Insights

Top Rated Stocks Most Active Stocks Top Potential Stocks Top Momentum Stocks Leaderboard

About Us Log In Sign Up Plans & Pricing Contact Us Terms of Use Privacy Policy

Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist

BIIB Stock Analysis & IQ Rating | Biogen

BIIB

Biogen

$179.89

+$3.76 | +2.14%

Set Alerts

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Headlines

52W High

$190.2

MKT CAP

$26.39B

52W Low

$110.04

VOL

$758.43K

P/E Ratio

16.4

AVG VOL

$1.98M

RSI

57.99

TREND

Uptrend

BIIB Stock IQ

Login to see Biogen (BIIB) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

BIIB Target Price

Login to display

Strengths

BIIB Rewards

Trading below its fair value

BIIB Rewards

Outperform the market

Risk Analysis

BIIB Risk Analysis

Earnings are forecast to decrease

Technical Indicators

BIIB Technical Indicators

5+ Days Up

BIIB Price Performance

$174.63 (+3.01%)

$153.43 (+17.25%)

$143.6 (+25.27%)

$136.57 (+31.72%)

1year

6month

3month

1month

BIIB Analysts Opinion

Overall standing based on market and analyst consensus. menu Hover over the category for more information

BIIB Analysts Opinion

BIIB Analysts opinion is negative and it remained unchanged from the past 3 months

BIIB Street Sentiment

Analysts perspectives on the stock desirability, trend direction and growth potential

80%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

50%

29%

67%

BIIB Street Sentiment

BIIB Street Sentiment is extremely bullish and have negative views on the near-term outlook

BIIB Risk Level

BIIB has Low risk level

Low

LOW

HIGH

BIIB Performance Sentiment

Sentiments overview associated with events and the stock performance

80%

20%

Positive

Negative

12 out of 15
events present

3 out of 15
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Key Price Levels

Average key support and resistance price levels

Support
Price

$174.83

Resistance
Price

$164.42

Current Price Range

$187.62

Show methods +

Analyst Consensus

Recent Upgrades and Downgrades

60%

Buy

Hold

Sell

Consensus Rating

BUY

3

2

0

Date

Action

Rating

Firm

Nov 22, 2025

Reiterate

Neutral

Piper Sandler

Nov 07, 2025

Upgrade

Buy

Stifel

Nov 01, 2025

Reiterate

Outperform

RBC

Sep 25, 2025

Initiate

Buy

Jefferies

Sep 25, 2025

Upgrade

Neutral

Goldman Sachs

Linked to BIIB

Close Price

Change

AMGN

Amgen

341.88

-0.31%

CHRS

Coherus BioSciences

2.16

-7.30%

BNTX

BioNTech

113.75

-2.59%

ALVO

Alvotech

5.37

-0.92%

Recently Viewed

Close Price

Change

BIIB

Biogen

179.89

+2.14%

MTZ

MasTec

240.48

-1.88%

GPCR

Structure Therapeutics In

88.45

+1.49%

OKTA

Okta

84.43

-1.41%

RBRK

Rubrik Inc.

55.95

-3.47%

BIIB Latest Analysis +

Analysts Estimate Biogen Inc. (BIIB) to Report a Decline in Earnings: What to Look Out for. Biogen (BIIB) doesnt possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Fri Jan 30, 2026

$179.89 | +2.14%

Earnings

Biogen Says FDA Grants Breakthrough Therapy Designation For Litifilimab To Treat CLE . (RTTNews) - Biogen Inc. (BIIB) announced Wednesday that the United States Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for litifilimab (BIIB059) for the treatment of cutaneous lupus erythematosus (CLE).

Wed Jan 28, 2026

$174.83 | +0.41%

Activity

Biogens Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus a Disease With No Targeted Treatment Options. CAMBRIDGE Mass. Jan. 28 2026 (GLOBE NEWSWIRE) -- Inc. (Nasdaq: BIIB) – announced today that the United States Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for litifilimab (BIIB059) for the treatment of cutaneous lupus erythematosus (CLE). Litifilimab is a first in-class humanized IgG1 monoclonal antibody (mAb) target

Wed Jan 28, 2026

$174.83 | +0.41%

Activity

FDA Grants Priority Review To Eisai And Biogens SBLA For LEQEMBI Subcutaneous Autoinjector . (RTTNews) - Eisai Co. Ltd. (ESALY ESALF 4523.T) and Biogen Inc. (BIIB) announced that the United States Food and Drug Administration has accepted for review Eisais Supplemental Biologics License Application (sBLA) for lecanemab-irmb (United States brand name: LEQEMBI) subcutaneous autoinjector

Mon Jan 26, 2026

$173.12 | +0.89%

Activity

FDA Accepts To Priority Review Eisai And Biogens LEQEMBI SBLA For Early Alzheimers Disease . (RTTNews) - Eisai Co. Ltd (4523.T ESALY.PK ESALF.PK) a Japanese commercial-stage biotechnology firm and Biogen Inc. (BIIB) said the United States Food and Drug Administration (FDA) has accepted for priority review Eisais Supplemental Biologics License Application (sBLA) for lecanema

Mon Jan 26, 2026

$173.12 | +0.89%

Activity

Looking Into Biogen Incs Recent Short Interest. BIIB) short interest as a percent of float has fallen 32.24% since its last report. According to exchange reported data there are now Short interest is the number of shares that have been sold short but have not yet been covered or closed out. is when a trader sells shares of a company they do not own with the hope that the price will ...

Fri Jan 23, 2026

$171.59 | -1.27%

Activity

Biogen Sees $1.26 Per Share Impact From IPR&D Milestone Expenses In Q4 . (RTTNews) - Biogen Inc. (BIIB) expects its fourth-quarter 2025 results to include approximately $222 million in acquired in-process research and development (IPR&D) upfront and milestone expenses on a pre-tax basis the company said in an SEC filing. The charge is expected to r

Wed Jan 14, 2026

$169.31 | -5.04%

Activity

Biogens Q4 preliminary EPS comes in below consensus.

Wed Jan 14, 2026

$169.31 | -5.04%

Earnings

Biogen Receives European Nod For High-Dose Regimen Of SPINRAZA In Spinal Muscular Atrophy . (RTTNews) - Biogen Inc. (BIIB) announced that the European Commission has granted marketing authorisation for a high-dose regimen of SPINRAZA comprised of 50 mg/5 mL and 28 mg/5 mL doses for 5q spinal muscular atrophy.

Tue Jan 13, 2026

$178.30 | -3.95%

Activity

Biogen Gains EU Approval For High-Dose SPINRAZA Regimen In SMA . (RTTNews) - Biogen Inc. (BIIB) announced that the European Commission has granted marketing authorization for a high dose regimen of SPINRAZA (nusinersen) which is comprised of 50 mg/5 mL and 28 mg/5 mL doses for the treatment of 5q spinal muscular atrophy (SMA).

Tue Jan 13, 2026

$178.30 | -3.95%

Activity

FAQ About BIIB Stock Insights

What is BIIB current stock price?

What are BIIB stock strengths?

What is BIIB Risk Level?

What is BIIB market cap and volume?

What is BIIB current Stock IQ?

Should I buy BIIB stock right now?

Is BIIB a Strong Buy right now?

What does a 'Strong Buy' rating mean for BIIB?

What does a 'Strong Sell' rating mean for BIIB?

What factors influence BIIB's Stock IQ?

Explore our BIIB Stock insights

In-Depth Market Analysis and Trends
Expert Insights on Market Dynamics
Tailored BIIB Stock Strategies
Effective Risk Management

FIND US ON

Receive our BIIB Daily Alerts

Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts

Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

BIIB

Biogen

Set Alerts

Current Price

$179.89

+$3.76 | +2.14%

52W High

$190.2

MKT CAP

$26.39B

52W Low

$110.04

VOL

$758.43K

P/E Ratio

16.4

AVG VOL

$1.98M

RSI

57.99

TREND

Uptrend

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Linked to BIIB

Symbol

Close

Change

AMGN

Amgen

341.88

-0.31%

CHRS

Coherus BioSciences

2.16

-7.30%

BNTX

BioNTech

113.75

-2.59%

ALVO

Alvotech

5.37

-0.92%

BIIB Street Sentiment

Analysts perspectives on the stock desirability, trend direction and growth potential

80%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

50%

29%

67%

BIIB Street Sentiment

BIIB Street Sentiment is extremely bullish and have negative views on the near-term outlook

BIIB Risk Level

BIIB has Low risk level

Low

LOW

HIGH

BIIB Performance Sentiment

Sentiments overview associated with events and the stock performance.

80%

20%

Positive

Negative

12 out of 15
events present

3 out of 15
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Key Price Levels

Average key support and resistance price levels

Support
Price

$174.83

Resistance
Price

$164.42

Current Price Range

$187.62

Show methods +

Latest Analyst Actions

Overall Wall Street Rating

60%

Buy

Hold

Sell

Consensus Rating

BUY

3

2

0

Date

Action

Rating

Firm

Nov 22, 2025

Reiterate

Neutral

Piper Sandler

Nov 07, 2025

Upgrade

Buy

Stifel

Nov 01, 2025

Reiterate

Outperform

RBC

Sep 25, 2025

Initiate

Buy

Jefferies

Sep 25, 2025

Upgrade

Neutral

Goldman Sachs

BIIB Stock IQ

Login to unlock Biogen (BIIB) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

Target Price

Login to display

Stock Insights

Strengths

BIIB Rewards

Trading below its fair value

BIIB Rewards

Outperform the market

Risk Analysis

BIIB Risk Analysis

Earnings are forecast to decrease

Technical Indicators

BIIB Technical Indicators

5+ Days Up

BIIB Latest Analysis

Analysts Estimate Biogen Inc. (BIIB) to Report a Decline in Earnings: What to Look Out for. Biogen (BIIB) doesnt possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Fri Jan 30, 2026

$179.89 | +2.14%

Earnings

Biogen Says FDA Grants Breakthrough Therapy Designation For Litifilimab To Treat CLE . (RTTNews) - Biogen Inc. (BIIB) announced Wednesday that the United States Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for litifilimab (BIIB059) for the treatment of cutaneous lupus erythematosus (CLE).

Wed Jan 28, 2026

$174.83 | +0.41%

Activity

Biogens Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus a Disease With No Targeted Treatment Options. CAMBRIDGE Mass. Jan. 28 2026 (GLOBE NEWSWIRE) -- Inc. (Nasdaq: BIIB) – announced today that the United States Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for litifilimab (BIIB059) for the treatment of cutaneous lupus erythematosus (CLE). Litifilimab is a first in-class humanized IgG1 monoclonal antibody (mAb) target

Wed Jan 28, 2026

$174.83 | +0.41%

Activity

FDA Grants Priority Review To Eisai And Biogens SBLA For LEQEMBI Subcutaneous Autoinjector . (RTTNews) - Eisai Co. Ltd. (ESALY ESALF 4523.T) and Biogen Inc. (BIIB) announced that the United States Food and Drug Administration has accepted for review Eisais Supplemental Biologics License Application (sBLA) for lecanemab-irmb (United States brand name: LEQEMBI) subcutaneous autoinjector

Mon Jan 26, 2026

$173.12 | +0.89%

Activity

FDA Accepts To Priority Review Eisai And Biogens LEQEMBI SBLA For Early Alzheimers Disease . (RTTNews) - Eisai Co. Ltd (4523.T ESALY.PK ESALF.PK) a Japanese commercial-stage biotechnology firm and Biogen Inc. (BIIB) said the United States Food and Drug Administration (FDA) has accepted for priority review Eisais Supplemental Biologics License Application (sBLA) for lecanema

Mon Jan 26, 2026

$173.12 | +0.89%

Activity

Looking Into Biogen Incs Recent Short Interest. BIIB) short interest as a percent of float has fallen 32.24% since its last report. According to exchange reported data there are now Short interest is the number of shares that have been sold short but have not yet been covered or closed out. is when a trader sells shares of a company they do not own with the hope that the price will ...

Fri Jan 23, 2026

$171.59 | -1.27%

Activity

Biogen Sees $1.26 Per Share Impact From IPR&D Milestone Expenses In Q4 . (RTTNews) - Biogen Inc. (BIIB) expects its fourth-quarter 2025 results to include approximately $222 million in acquired in-process research and development (IPR&D) upfront and milestone expenses on a pre-tax basis the company said in an SEC filing. The charge is expected to r

Wed Jan 14, 2026

$169.31 | -5.04%

Activity

Biogens Q4 preliminary EPS comes in below consensus.

Wed Jan 14, 2026

$169.31 | -5.04%

Earnings

Biogen Receives European Nod For High-Dose Regimen Of SPINRAZA In Spinal Muscular Atrophy . (RTTNews) - Biogen Inc. (BIIB) announced that the European Commission has granted marketing authorisation for a high-dose regimen of SPINRAZA comprised of 50 mg/5 mL and 28 mg/5 mL doses for 5q spinal muscular atrophy.

Tue Jan 13, 2026

$178.30 | -3.95%

Activity

Biogen Gains EU Approval For High-Dose SPINRAZA Regimen In SMA . (RTTNews) - Biogen Inc. (BIIB) announced that the European Commission has granted marketing authorization for a high dose regimen of SPINRAZA (nusinersen) which is comprised of 50 mg/5 mL and 28 mg/5 mL doses for the treatment of 5q spinal muscular atrophy (SMA).

Tue Jan 13, 2026

$178.30 | -3.95%

Activity

Discover BIIB Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends and the future potential of BIIB. We're here to help you make informed investment decisions today.

FIND US ON

Receive our BIIB Daily Alerts

Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

BIIB Stock trends

BIIB Stock performance

BIIB Stock analysis

BIIB investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner Insights

Financial Reports

Disclaimer: Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor. The Readiness Indicators, Sentiment Indicators and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses. Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing BIIB

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence and cutting-edge intelligence.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing BIIB

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence and cutting-edge intelligence.

BIIB Stock Analysis & IQ Rating | Biogen

BIIB Stock IQ

BIIB Target Price

BIIB Analysts Opinion

BIIB Street Sentiment

BIIB Risk Level

BIIB Performance Sentiment

Key Price Levels

Analyst Consensus

Explore our BIIB Stock insights

Receive our BIIB Daily Alerts

BIIB Street Sentiment

BIIB Risk Level

Key Price Levels

Latest Analyst Actions

Discover BIIB Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends and the future potential of BIIB. We're here to help you make informed investment decisions today.

Receive our BIIB Daily Alerts

BIIB Alerts